- HETEROCYCLIC COMPOUNDS, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOF
-
The present invention provides a heterocyclic compound represented by the formula (I), its stereoisomers, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions thereof, and their use in preparing a medicament for the prevention and/or treatment of central nervous system disease.
- -
-
Paragraph 0385
(2017/07/15)
-
- Design, synthesis and evaluation of small molecule CD4-mimics as entry inhibitors possessing broad spectrum anti-HIV-1 activity
-
Since our first discovery of a CD4-mimic, NBD-556, which targets the Phe43 cavity of HIV-1 gp120, we and other groups made considerable progress in designing new CD4-mimics with viral entry-antagonist property. In our continued effort to make further progress we have synthesized twenty five new analogs based on our earlier reported viral entry antagonist, NBD-11021. These compounds were tested first in HIV-1 Env-pseudovirus based single-cycle infection assay as well as in a multi-cycle infection assay. Four of these new compounds showed much improved antiviral potency as well as cytotoxicity. We selected two of the best compounds 45A (NBD-14009) and 46A (NBD-14010) to test against a panel of 51 Env-pseudotyped HIV-1 representing diverse subtypes of clinical isolates. These compounds showed noticeable breadth of antiviral potency with IC50of as low as 150 nM. These compounds also inhibited cell-to-cell fusion and cell-to-cell HIV-1 transmission. The study is expected to pave the way of designing more potent and selective HIV-1 entry inhibitors targeted to the Phe43 cavity of HIV-1 gp120.
- Curreli, Francesca,Belov, Dmitry S.,Ramesh, Ranjith R.,Patel, Naisargi,Altieri, Andrea,Kurkin, Alexander V.,Debnath, Asim K.
-
p. 5988 - 6003
(2016/10/30)
-
- Design and synthesis of neuroprotective methylthiazoles and modification as NO-chimeras for neurodegenerative therapy
-
Learning and memory deficits in Alzheimers disease (AD) result from synaptic failure and neuronal loss, the latter caused in part by excitotoxicity and oxidative stress. A therapeutic approach is described that uses NO-chimeras directed at restoration of both synaptic function and neuroprotection. 4-Methylthiazole (MZ) derivatives were synthesized, based upon a lead neuroprotective pharmacophore acting in part by GABAA receptor potentiation. MZ derivatives were assayed for protection of primary neurons against oxygen-glucose deprivation and excitotoxicity. Selected neuroprotective derivatives were incorporated into NO-chimera prodrugs, coined nomethiazoles. To provide proof of concept for the nomethiazole drug class, selected examples were assayed for restoration of synaptic function in hippocampal slices from AD-transgenic mice, reversal of cognitive deficits, and brain bioavailability of the prodrug and its neuroprotective MZ metabolite. Taken together, the assay data suggest that these chimeric nomethiazoles may be of use in treatment of multiple components of neurodegenerative disorders, such as AD.
- Qin, Zhihui,Luo, Jia,Vandevrede, Lawren,Tavassoli, Ehsan,Fa, Mauro,Teich, Andrew F.,Arancio, Ottavio,Thatcher, Gregory R. J.
-
experimental part
p. 6784 - 6801
(2012/10/07)
-
- Synthesis, in vitro and in vivo activity of thiamine antagonist transketolase inhibitors
-
Tumor cells extensively utilize the pentose phosphate pathway for the synthesis of ribose. Transketolase is a key enzyme in this pathway and has been suggested as a target for inhibition in the treatment of cancer. In a pharmacodynamic study, nude mice with xenografted HCT-116 tumors were dosed with 1 ('N3′-pyridyl thiamine'; 3-(6-methyl-2-amino-pyridin-3-ylmethyl)-5-(2-hydroxy-ethyl)-4-methyl-thiazol-3-ium chloride hydrochloride), an analog of thiamine, the co-factor of transketolase. Transketolase activity was almost completely suppressed in blood, spleen, and tumor cells, but there was little effect on the activity of the other thiamine-utilizing enzymes α-ketoglutarate dehydrogenase or glucose-6-phosphate dehydrogenase. Synthesis and SAR of transketolase inhibitors is described.
- Thomas, Allen A.,Le Huerou,De Meese,Gunawardana, Indrani,Kaplan, Tomas,Romoff, Todd T.,Gonzales, Stephen S.,Condroski, Kevin,Boyd, Steven A.,Ballard, Josh,Bernat, Bryan,DeWolf, Walter,Han, May,Lee, Patrice,Lemieux, Christine,Pedersen, Robin,Pheneger, Jed,Poch, Greg,Smith, Darin,Sullivan, Francis,Weiler, Solly,Wright, S. Kirk,Lin, Jie,Brandhuber, Barb,Vigers, Guy
-
p. 2206 - 2210
(2008/12/20)
-
- Remarkable synthesis of 2-(Z)-6-(E)-4H- [1,4]-thiazepin-5-ones by zwitterionic rhodium-catalyzed chemo- and regioselective cyclohydrocarbonylative ring expansion of acetylenic thiazoles
-
Cyclohydrocarbonylative ring expansion of acetylenic thiazoles in the presence of CO, H2, and catalytic quantities of the zwitterionic rhodium complex η6-C6H5BPh3) -Rh+(1,5-COD) and triphenyl phosphite affords thiazepinones in 61 to 90% yields. This novel transformation of a 5- to a 7-membered heterocycle is readily applied to acetylenic thiazoles containing hydro, alkyl, alkyl halide, vinyl, and benzo substitutents in positions 4 and 5 of the thiazole ring in addition to alkyl-, ether-, ester-, vinyl-, and aryl-substituted alkynes at position 2.
- Van den Hoven,Alper
-
p. 1017 - 1022
(2007/10/03)
-
- Thiamin Biosynthesis in Yeast. Origin of the Five-Carbon Unit of the Thiazole Moiety
-
Radioactivity from D--, D--, and D-glucose, from D-fructose, and from glycerol is incorporated nonrandomly into the C5 chain of the thiazole moiety of thiamin in Saccharomyces cerevisiae.The incorporation pattern leads to inference that the C5 chain is derived from a 2-pentulose, which is generated from the hexose precursors by the oxidative as well as by the nonoxidative pentose phosphate pathway.A chemically rational scheme for the biogenesis of the thiazole moiety of thiamin is presented.
- White, Robert L.,Spenser, Ian D.
-
p. 4934 - 4943
(2007/10/02)
-